

January 7, 2021

COM-2021-003

Dear provider of healthcare-related services,

On January 4, 2021, the Food and Drug Administration (FDA) issued press announcement reminding the importance of following the authorized dosing schedules for the two mRNA coronavirus disease 2019 (COVID-19) vaccines that have now shown effectiveness in preventing COVID-19, in order to safely receive the level of protection observed in the large randomized trials supporting their effectiveness.

At this time, suggesting changes to the FDA-authorized dosing or schedules (e.g., reducing the number of doses, extending the length of time between doses, changing the dose [half-dose], or mixing and matching vaccines in order to immunize more people against COVID-19) of the vaccines is premature and not supported by available scientific evidence. Without appropriate data supporting changes to the FDA-authorized dosing or schedules, there is a significant risk of placing public health at risk. The FDA continues to strongly recommend following the FDA-authorized dosing schedule for each COVID-19 vaccine as available data continue to support the use of two specified doses of each authorized vaccine at specified intervals.

- For the Pfizer-BioNTech COVID-19 vaccine, the interval is 21 days between the first and second dose.
- For the Moderna COVID-19 vaccine, the interval is 28 days between the first and second dose.

Additional information on this press announcement can be found at the [FDA's Press Announcements portal](#). Additional information on the vaccines authorized by the FDA for emergency use can be found at the [FDA's COVID-19 Vaccines portal](#).

The situation with the COVID-19 pandemic is dynamic and continuously changing. We strongly encourage the frequent revision of updated information provided by the FDA and the Centers for



Control and Prevention (CDC) to assure that your practices are consistent with the most actualized information.

PharmPix is committed to our members' health and wellness. It is our priority to offer high-quality services and support practices for health promotion and diseases prevention. If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252, extension 137. Also, you can access our recent communications at our providers' portal: <https://www.pharmpix.com/providers/>.

Regards,

Clinical Department

References:

1. FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines. U.S. Food and Drug Administration. (2021). Retrieved January 2021, from <https://www.fda.gov/news-events/press-announcements/fda-statement-following-authorized-dosing-schedules-covid-19-vaccines>.

